Assistant Professor of Medicine, Massachusetts General Hospital
Oncology
Dr. Philip C. Amrein, MD
|
|
Give Review
Philip C. Amrein, MD works in the field of Oncology. He studied medicine at Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is a one of the best medicals schools. Johns Hopkins University School of Medicine has a rank of 3 in research and a 29 in primary care He has 1 awards "Meaningful Use Stage 1 Certification". Philip Amrein has written publications. He has 62 publications published with PubMed. The lastest paper is: 'An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8722,...' He accepts all Medicare patients.
Publications
- Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed Acute lymphoblastic leukemia.
- Drug-induced death signaling strategy rapidly predicts Cancer response to chemotherapy.
- Presentation and outcomes among patients with isolated Myeloid sarcoma: a Surveillance, Epidemiology, and End Results database analysis.
- Population-based disparities in survival among patients with core-binding factor Acute myeloid leukemia: A SEER database analysis.
- D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice.
- A phase II study of the EGFR inhibitor gefitinib in patients with Acute myeloid leukemia.
- Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and Acute myeloid leukemia (AML).
- Association between baseline body mass index (BMI) and overall survival among patients over age 60 with Acute myeloid leukemia (AML).
- Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Ac...
- Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed Acute myeloid leukemia, to assess disease activity and therapeutic response.
- Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal Acute myeloid leukemia (CN-AML) and FLT3ITD.
- Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations.
- Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
- Genomic alterations in Myeloid neoplasms with novel, apparently balanced translocations.
- Diffuse Cellular and fibrosing interstitial pneumonitis with desquamative interstitial pneumonitis-like features associated with myeloid neoplasia.
- Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with Acute myelogenous leukemia.
- Case records of the Massachusetts General Hospital. Case 26-2007 - a 61-year-old man with recurrent fevers.
- Case records of the Massachusetts General Hospital. Case 15-2006. A 46-year-old woman with sudden onset of abdominal distention.
- Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced...
- Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for Acute myeloid leukemia in adults under 60...
- Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid Tumors.
- HER2 expression in salivary gland Carcinomas: dependence on histological subtype.
- A new case of t(11;17)(q23;q21) with MLL rearrangement.
- Faith, identity, and Leukemia: when blood products are not an option.
- Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of Myeloid malignancies.
- A phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous Cell carcinoma of the head and neck.
- A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-Cell cancer of the head and neck.
- Treatment of patients with recurrent and primary refractory Acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based r...
- A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therap...
- Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous Cell carcinoma of the head and neck.
- Choroidal metastasis from olfactory neuroblastoma (esthesioneuroblastoma).
- An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory Acute myeloid leukemia: results of 8722,...
- Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for Acute myeloid leukemia with aziridin...
- Successful treatment of esthesioneuroblastoma and neuroendocrine Carcinoma with combined chemotherapy and proton radiation. Results in 9 cases.
- Intensive recombinant interleukin-2 and alpha-interferon therapy in patients with advanced head and neck squamous Carcinoma.
- Comparison of filtration leukapheresis and centrifugation leukapheresis in treatment of lymphosarcoma cell Leukemia.
- Aspirin-induced prolongation of bleeding time and perioperative blood loss.
- Phase II study of AMSA in patients with metastatic breast cancer: a Cancer and Leukemia Group B study.
- Prevention of degradation of human polymorphonuclear leukocyte proteins by diisopropylfluorophosphate.
- Phase II study of amsacrine in metastatic renal cell carcinoma: a Cancer and Leukemia Group B study.
- Three-dimensional structure of actin filaments and of an actin gel made with actin-binding protein.
- Treatment of metastatic ovarian carcinoma with amsacrine: a cancer and Leukemia group B phase II study.
- The treatment of melanoma with m-AMSA. A Cancer and Leukemia Group B phase II study.
- Phase II trial of amsacrine in patients with hepatoma: a Cancer and Leukemia Group B study.
- Cisplatin-vincristine-bleomycin therapy in squamous Cell carcinoma of the head and neck.
- An automated system for measurement of leukocyte metabolism.
- A rapid automated system for measurement of antibody titers.
- Phase II trial of m-AMSA therapy in refractory Hodgkin's disease and non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 7972.
- Treatment of squamous-Cell carcinoma of the head and neck with cisplatin and 5-fluorouracil.
- Treatment of relapsed and refractory Acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase I study.
- Current chemotherapy of head and neck Cancer.
- Compositional changes in vertebral bone marrow during treatment for Acute leukemia: assessment with quantitative chemical shift imaging.
- Treatment of recurrent head and neck Cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate.
- Hematologic changes in anorexia nervosa.
- Sézary syndrome with warm and cold erythrocyte autoantibodies.
- Faith and freedom: Leukemia in Jehovah Witness minors.
- Herceptin in patients with advanced or metastatic salivary gland Carcinomas. A phase II study.
- ELF4 is fused to ERG in a case of Acute myeloid leukemia with a t(X;21)(q25-26;q22).
- The potential for dasatinib in treating chronic lymphocytic leukemia, Acute myeloid leukemia, and myeloproliferative neoplasms.
- Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy.
- Clinical outcome of patients with Acute promyelocytic leukemia and FLT3 mutations.
Schools
Johns Hopkins University School of Medicine
Waterbury Hospital
Massachusetts General Hospital
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Basal Cell Carcinoma
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
Education
-
Massachusetts General Hospital -
Johns Hopkins University School of Medicine
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1073589578 | |
| NPPES Provider LastName | AMREIN | |
| NPPES Provider FirstName | PHILIP | |
| NPPES Provider ZIPCode | 02114 | |
| NPPES Provider State | MA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 349.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 18.0 | |
| Percent Opioid Claims | 5.16 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1073589578 |
| Last Name Of The Provider | AMREIN |
| First Name Of The Provider | PHILIP |
| View All |
Similar Doctors
|
|
Dr. Kimmie Ng, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven J. Isakoff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lauren C. Harshman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel G. Stover, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter C. Everett, MD |
|
Dr. Adam Lerner, MD
This Doctor is OpenDoctor Recommended.
|